» Articles » PMID: 36292685

Influence of Parent-of-Origin on Intellectual Outcomes in the Chromosome 22q11.2 Deletion Syndrome

Overview
Journal Genes (Basel)
Publisher MDPI
Date 2022 Oct 27
PMID 36292685
Authors
Affiliations
Soon will be listed here.
Abstract

Learning and intellectual disabilities are hallmark features of 22q11.2 deletion syndrome. Data are limited, however, regarding influences on full-scale IQ (FSIQ). Here, we investigated possible 22q11.2 deletion parent-of-origin effects. In 535 individuals, we compared FSIQ (≥50), 481 with de novo and 54 with inherited 22q11.2 deletions. In the subsets with data available, we examined parent-of-origin effects on FSIQ. We used linear regression models to account for covariates. Median FSIQ was significantly higher in de novo vs. inherited deletions (77; range 50−116 vs. 67; range 50−96, p < 0.0001). Results remained significant using a regression model accounting for age at IQ testing, sex and cohort site. No significant parent-of-origin differences in FSIQ were observed for de novo deletions (n = 81, 63.0% maternal; p = 0.6882). However, median FSIQ was significantly lower in maternally than in paternally inherited familial deletions (65, range 50−86 vs. 71.5, range 58−96, respectively, p = 0.0350), with the regression model indicating an ~8 point decrement in FSIQ for this variable (p = 0.0061). FSIQ is higher on average in de novo than in inherited 22q11.2 deletions, regardless of parental origin. However, parent-of-origin appears relevant in inherited deletions. The results have potential clinical implications with further research needed to delineate possible actionable mechanisms.

Citing Articles

22q11.2 Deletion Syndrome: Influence of Parental Origin on Clinical Heterogeneity.

de Wallau M, Xavier A, Moreno C, Kim C, Mendes E, Ribeiro E Genes (Basel). 2024; 15(4).

PMID: 38674452 PMC: 11050591. DOI: 10.3390/genes15040518.


Prenatal Screening and Diagnostic Considerations for 22q11.2 Microdeletions.

Blagowidow N, Nowakowska B, Schindewolf E, Grati F, Putotto C, Breckpot J Genes (Basel). 2023; 14(1).

PMID: 36672900 PMC: 9858737. DOI: 10.3390/genes14010160.

References
1.
Swillen A, Moss E, Duijff S . Neurodevelopmental outcome in 22q11.2 deletion syndrome and management. Am J Med Genet A. 2018; 176(10):2160-2166. PMC: 6202262. DOI: 10.1002/ajmg.a.38709. View

2.
Campbell I, Sheppard S, Crowley T, McGinn D, Bailey A, McGinn M . What is new with 22q? An update from the 22q and You Center at the Children's Hospital of Philadelphia. Am J Med Genet A. 2018; 176(10):2058-2069. PMC: 6501214. DOI: 10.1002/ajmg.a.40637. View

3.
Delio M, Guo T, McDonald-McGinn D, Zackai E, Herman S, Kaminetzky M . Enhanced maternal origin of the 22q11.2 deletion in velocardiofacial and DiGeorge syndromes. Am J Hum Genet. 2013; 92(3):439-47. PMC: 3591861. DOI: 10.1016/j.ajhg.2013.01.018. View

4.
Blagojevic C, Heung T, Theriault M, Tomita-Mitchell A, Chakraborty P, Kernohan K . Estimate of the contemporary live-birth prevalence of recurrent 22q11.2 deletions: a cross-sectional analysis from population-based newborn screening. CMAJ Open. 2021; 9(3):E802-E809. PMC: 8373039. DOI: 10.9778/cmajo.20200294. View

5.
Grand K, Katz L, Crowley T, Moss E, Lessig M, Bamba V . The impact of hypocalcemia on full scale IQ in patients with 22q11.2 deletion syndrome. Am J Med Genet A. 2018; 176(10):2167-2171. PMC: 6214204. DOI: 10.1002/ajmg.a.40535. View